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In summary, our data indicate an increased risk of SBP in cir-
rhotic patients carrying the TLR2 Arg753Gln polymorphism (OR
5.6; 95% CI 1.4–22.8) and add further evidence for the relevance
of TLR2 signaling in the development of SBP provided by Nis-
chalke et al. A prospective validation of potential genetic markers
in larger cohorts is needed to conclusively evaluate the geneti-
cally attributable risk for SBP in patients with cirrhosis and
ascites.
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Letters to the EditorReply to: ‘‘Further evidence for the relevance of TLR2 gene variants
in spontaneous bacterial peritonitis’’To the Editor:
The potential role of speciﬁc TLR2 gene polymorphisms as
host risk factors for spontaneous bacterial peritonitis
We are grateful for the comments of Bruns and co-workers,
which together with our report suggest a role of TLR2 in the
defence against bacterial infection of ascites. First, they con-
ﬁrmed the trend observed in our study that the TLR2 Arg753Gln
polymorphism might be a potential risk factor for spontaneous
bacterial peritonitis (SBP) in end-stage liver cirrhosis. On the
other hand their study produced divergent results concerning
the TLR2 16934A>T polymorphism. This draws attention to
some limitations of the studies, in particular the fact that causa-
tive organisms had been identiﬁed only infrequently. In our
study, we observed a signiﬁcant contribution from Gram-positive
organisms, possibly reﬂecting the broad use of antibiotic prophy-
laxis mainly targeted against Gram-negative agents, while details
of the bacterial spectrum were not disclosed in the report by
Bruns et al. Thus, we cannot exclude the possibility that the
TLR2 polymorphisms might confer differential susceptibility to
distinct groups of micro-organisms.
Beyond that, the data in the report of Bruns and co-workers
have not been corrected for potential confounders. Thus, it might
be possible that their apparent association between the TLR2
Arg753Gln polymorphism and SBP might actually reﬂect the cor-
relation between this polymorphism and ascitic protein levels in
their study population. In contrast, we performed Cox regression
analysis, which identiﬁed protein concentration, the presence of
NOD2 risk alleles and GT-repeats greater than 20 in both alleles,
in intron 2 of the TLR2 gene, as independent risk factors for SBP.
Indeed, we assume that the GT repeat polymorphism rather than
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Interaction between IL28B and PNPLA3 genotypes
in the pathogenesis of steatosis in chronic
hepatitis C non genotype-3 patients
To the Editor:
Steatosis is frequently observed in patients with chronic hepatitis
C (CHC), and is associated with ﬁbrosis progression and treat-
ment failure [1,2]. Tillmann et al. recently reported a negative
association between the interleukin 28B (IL28B) rs12979860 CC
genotype, predicting sustained virological response [3], and stea-
tosis in genotype-1 CHC [4]. However, whether this association
was independent of other genetic factors was not evaluated.
The patatin-like phospholipase domain-containing 3
(PNPLA3) rs738409 polymorphism is a strong determinant of
hepatic fat accumulation and steatohepatitis [5,6], but also
inﬂuences steatosis and ﬁbrosis progression in CHC [7–9]. A
previous study [7] also reported an association between IL28B
rs12980275 genotype and steatosis in CHC non genotype-3
patients, but the rs12979860 IL28B polymorphism was not
tested and the interaction with PNPLA3 genotype was not ana-
lyzed in details.
We now conﬁrm the negative association of rs12979860 CC
with histologically-determined steatosis (111/184, 60% vs. 266/
383, 69%; p = 0.036) and steatosis grade >1 (17/184, 9% vs. 70/
383 18%; p = 0.0059) in 567 naïve, consecutive, non genotype-3
patients from referral centers in Milan and Vienna, without exces-
sive alcohol intake (>i.e. 60/40 g/day for M/F), HBsAg positivity,
and HIV infection. Sixty-ﬁve percent of patients were genotype-
1, and 20% had cirrhosis. A similar trendwas observed for all geno-
types. Importantly, as shown in Table 1, the association between
IL28B genotype and steatosiswas independent of acquired risk fac-
tors, and of the PNPLA3 GG genotype. Interestingly however, the
rs12979860 CC genotype protected form steatosis in patients posi-
tive, but not in those negative for the PNPLA3 G variant at risk (49/
78, 63% vs. 144/187, 77%, p = 0.022 and 62/106, 58% vs. 74/196,
62%, p = 0.52, respectively). Therefore, data suggest the possibility
that an interaction occurs between IL28B and PNPLA3 genotypes in
the pathogenesis of steatosis in CHC non genotype-3 patients.
the single nucleotide exchange16934T>A is associated with dif-
ferences in TLR2 functionality. Of note, a search for possible tran-
scription factor binding sites with TFSEARCH (http://
www.cbrc.jp/research/db/TFSEARCH.html) did not provide evi-
dence that the 16934T>A mutation itself leads to differences
in TLR2 gene expression. In contrast, the number of GT repeats
in intron 2 of the TLR2 gene has been shown to be linked with dif-
ferential cytokine responses [1]. Thus, the difference in
16934A>T allele frequencies between patients with and with-
out SBP is more likely to reﬂect association with the numbers
of TLR2 GT repeats rather than an effect of the SNP itself. Since
Bruns et al. did not report on the TLR2 GT repeat polymorphism,
we do not know if a similar association also exists in their
patients’ sample. In particular, alleles with long GT repeats
(>20) – the risk factor for SBP in our study – are found more often
in association with both the homozygous 16934T/T and the het-
erozygous 16934A/T genotypes. Interestingly, the distribution
of alleles shown by Bruns and co-workers indicates SBP to have
occurred most often among heterozygous carriers of the
16934A>T polymorphism. This particular feature and the over-
all small number of observed SBP episodes (25/119 = 21%) may
have resulted in the fact that 16934T/T homozygosity was not
conﬁrmed by the work of Bruns and co-workers.
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